Chronos Archive seal
The Human Record

Ida B. Wells

Case HR-ET022-TD · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
July 16, 1862 – March 25, 1931
Synthetic DOB
1862-07-16
Index visit
1931-01-05 at age 68
Synthetic MRN
HR-ET022-SYN-TD

Teaching objective: Chronic kidney disease found in time in a 68-year-old Black woman, a journalist and civic leader in Chicago, who comes in tired with swollen ankles. The teaching contrast is her documented death from kidney failure after a brief illness: here the disease is found, staged and treated years before kidney failure. The episode covers the race-free CKD-EPI 1926 equations (creatinine, then creatinine with cystatin C) and the history of race-based eGFR delaying the recognition and referral of Black patients, as the NKF-ASN Task Force described; staging on the KDIGO 1929 heat map with the urine albumin-to-creatinine ratio and the kidney failure risk equation; finding the cause (home blood pressure, diabetes screening, urinalysis, kidney ultrasound, and a monoclonal protein screen); APOL1 genetic testing offered with counseling and left to her choice; an ARB and an SGLT2 inhibitor with potassium and creatinine checks; blood pressure control; a statin; stopping naproxen; anemia and mineral and bone checks; vaccinations; a nephrology consultation; and shared decisions about kidney replacement options should the disease progress, under the KDIGO 1929 guideline, the 1930 AHA/ACC blood pressure guideline and the CMID chronic kidney disease monograph.

Historical timeline

DateEventClaims
July 16, 1862Born enslaved in Holly Springs, Mississippi.CLM-0001
autumn 1878Both parents and an infant brother died in the yellow fever epidemic; at 16 she took charge of her siblings.CLM-0002
1895A Red Record published.CLM-0003
June 27, 1895Married Ferdinand L. Barnett in Chicago.CLM-0004
1909Signed the call for the conference that led to the NAACP.CLM-0005
1927Began writing her autobiography.CLM-0007
1930Ran for the Illinois State Senate.CLM-0006
March 25, 1931Died in Chicago after a brief illness, of kidney disease (uremia), at 68.CLM-0008, CLM-0009

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Ida B. Wells was born enslaved on July 16, 1862, in Holly Springs, Mississippi, during the Civil War. confirmed Ida B. Wells supports
Ida B. Wells-Barnett (biography) supports
DeCosta-Willis M. Wells-Barnett, Ida B. supports
HISTMED Master Roster v3 context
D In the yellow fever epidemic of 1878, when she was 16, both her parents and an infant brother died; she left school and took on the care of her surviving younger siblings, teaching to support them.
Anchors the family history and the early loss and responsibility in her social history. The causes of death are as the sources give them.
confirmed Ida B. Wells supports
Ida B. Wells-Barnett (biography) supports
Wells-Barnett, Ida (1862-1931), Women in World History: A Biographical Encyclopedia supports
Guide to the Ida B. Wells Papers 1884-1976 (biographical note) supports
D She was an investigative journalist and editor who documented lynching in the United States, notably in A Red Record (1895), and campaigned against it for the rest of her life; she was also a suffragist and civil rights leader.
Anchors her occupation and her habit of checking every figure for herself in the modern social history.
confirmed Ida B. Wells-Barnett (biography) supports
Ida B. Wells supports
D On June 27, 1895, she married the Chicago attorney Ferdinand L. Barnett, kept her own name alongside his, and settled in Chicago; they had four children. confirmed DeCosta-Willis M. Wells-Barnett, Ida B. supports
Ida B. Wells supports
D She signed the call for the 1909 conference that led to the National Association for the Advancement of Colored People and is considered one of its founders, though she was left off the list of its founding committee and later drew away from it. confirmed DeCosta-Willis M. Wells-Barnett, Ida B. supports
Ida B. Wells supports
Ida B. Wells-Barnett (biography) supports
Guide to the Ida B. Wells Papers 1884-1976 (biographical note) supports
D In 1930 she ran, unsuccessfully, for the Illinois State Senate.
Anchors her continued public work in the year before the modern episode's true-frame dates.
confirmed Ida B. Wells-Barnett (biography) supports
Guide to the Ida B. Wells Papers 1884-1976 (biographical note) supports
D She began writing her autobiography in her last years; it was published after her death as Crusade for Justice: The Autobiography of Ida B. Wells, edited by her youngest daughter, Alfreda M. Duster.
Anchors the memoir she is writing in the modern social history.
confirmed Guide to the Ida B. Wells Papers 1884-1976 (biographical note) supports
Wells-Barnett, Ida (1862-1931), Women in World History: A Biographical Encyclopedia supports
D She died in Chicago on March 25, 1931, at 68, after a brief illness; the cause is given as kidney disease or uremia (uremic poisoning).
History after the modern episode. The anchor for the modern kidney episode: uremia means kidney failure. Sources differ on the day of death (see the editorial resolutions).
confirmed DeCosta-Willis M. Wells-Barnett, Ida B. supports
Ida B. Wells supports
Wells-Barnett, Ida (1862-1931), Women in World History: A Biographical Encyclopedia supports
Ida B. Wells-Barnett (biography) context
Guide to the Ida B. Wells Papers 1884-1976 (biographical note) context
R Whether she had chronic kidney disease before her final illness, and what caused her kidney failure, is not recorded in any source consulted; a short final illness ending in uremia is compatible with acute kidney failure, with chronic kidney disease made worse by an acute illness, or with long-standing kidney disease that had not been recognized.
Retrospective interpretation only. The chronic kidney disease, high blood pressure and every finding in the modern episode are synthetic; the modern episode shows kidney disease found in time, not a claim about her real kidneys.
possible Ida B. Wells derived_from
Wells-Barnett, Ida (1862-1931), Women in World History: A Biographical Encyclopedia derived_from
DeCosta-Willis M. Wells-Barnett, Ida B. derived_from

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established resolved confirmed active CLM-0008, CLM-0009
S Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm resolved confirmed active
S Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney disease active confirmed active CLM-0008, CLM-0009
S Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7% active confirmed both_with_link CLM-0008, CLM-0009
S Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tiredness active confirmed active
S Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normal active confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 1931-01-05 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1931-01-05 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1931-01-05 Carbon dioxide, total [Moles/volume] in Serum or Plasma 22 mmol/L
Reference Keep at 22 or above in kidney disease
http://loinc.org · 2028-9
S 1931-01-05 Urea nitrogen [Mass/volume] in Serum or Plasma 28 mg/dL (high)
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 1931-01-05 Glucose [Mass/volume] in Serum or Plasma 94 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1931-01-05 Creatinine [Mass/volume] in Serum or Plasma 1.42 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1931-01-05 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1926)/1.73 sq M 40 mL/min/1.73 m² (low)
Reference 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4
http://loinc.org · 98979-8
S 1931-01-05 Cystatin C [Mass/volume] in Serum or Plasma 1.68 mg/L (high)
Reference 0.53-0.95 mg/L
http://loinc.org · 33863-2
S 1931-01-05 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI 1926)/1.73 sq M 38 mL/min/1.73 m² (low)
Reference The confirmatory estimate KDIGO prefers when decisions depend on accuracy; 30 to 44 is G3b
http://loinc.org · 98980-6
S 1931-01-05 Albumin/Creatinine [Mass Ratio] in Urine 240 mg/g (high)
Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)
http://loinc.org · 9318-7
S 1931-01-05 Hemoglobin A1c/Hemoglobin.total in Blood 5.6%
Reference Below 5.7% is normal; 6.5% or higher is diabetes
http://loinc.org · 4548-4
S 1931-01-05 Hemoglobin [Mass/volume] in Blood 11.2 g/dL (low)
Reference Anemia in women is below 12.0 g/dL
http://loinc.org · 718-7
S 1931-01-05 Ferritin [Mass/volume] in Serum or Plasma 168 ng/mL
Reference 30-300 ng/mL
http://loinc.org · 2276-4
S 1931-01-05 Iron saturation [Mass Fraction] in Serum or Plasma 24%
Reference 20-50%
http://loinc.org · 2502-3
S 1931-01-05 Calcium [Mass/volume] in Serum or Plasma 9.2 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 1931-01-05 Phosphate [Mass/volume] in Serum or Plasma 3.8 mg/dL
Reference 2.5-4.5 mg/dL
http://loinc.org · 2777-1
S 1931-01-05 Parathyrin.intact [Mass/volume] in Serum or Plasma 84 pg/mL (high)
Reference 15-65 pg/mL
http://loinc.org · 2731-8
S 1931-01-05 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 17 ng/mL (low)
Reference Below 20 ng/mL deficient; 20 to 29 insufficient
http://loinc.org · 62292-8
S 1931-01-05 Cholesterol [Mass/volume] in Serum or Plasma 214 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 1931-01-05 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 136 mg/dL (high)
Reference <=99 mg/dL
http://loinc.org · 13457-7
S 1931-01-05 Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 mg/dL
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 1931-01-05 Triglyceride [Mass/volume] in Serum or Plasma 128 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 1931-01-05 Thyrotropin [Units/volume] in Serum or Plasma 1.9 mIU/L
Reference 0.4-4.5 mIU/L
http://loinc.org · 3016-3
S 1931-01-05 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 1931-01-20 Albumin/Creatinine [Mass Ratio] in Urine 228 mg/g (high)
Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)
http://loinc.org · 9318-7
S 1931-02-03 Sodium [Moles/volume] in Serum or Plasma 138 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1931-02-03 Potassium [Moles/volume] in Serum or Plasma 4.9 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1931-02-03 Carbon dioxide, total [Moles/volume] in Serum or Plasma 22 mmol/L
Reference Keep at 22 or above in kidney disease
http://loinc.org · 2028-9
S 1931-02-03 Urea nitrogen [Mass/volume] in Serum or Plasma 30 mg/dL (high)
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 1931-02-03 Creatinine [Mass/volume] in Serum or Plasma 1.5 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1931-02-03 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1926)/1.73 sq M 38 mL/min/1.73 m² (low)
Reference 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4
http://loinc.org · 98979-8
S 1931-03-03 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1931-03-03 Potassium [Moles/volume] in Serum or Plasma 4.8 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1931-03-03 Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 mmol/L
Reference Keep at 22 or above in kidney disease
http://loinc.org · 2028-9
S 1931-03-03 Urea nitrogen [Mass/volume] in Serum or Plasma 31 mg/dL (high)
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 1931-03-03 Creatinine [Mass/volume] in Serum or Plasma 1.56 mg/dL (high)
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1931-03-03 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1926)/1.73 sq M 36 mL/min/1.73 m² (low)
Reference 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4
http://loinc.org · 98979-8
S 1931-02-17 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 1931-02-17 Total score [Mini-Cog] 5 http://loinc.org · 72233-0
S 1931-02-17 Total score [AUDIT-C] 1 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
1931-01-05Body height157 cm8302-2S
1931-01-05Body weight70.4 kg29463-7S
1931-01-05Body mass index (BMI) [Ratio]28.6 kg/m239156-5S
1931-01-05Systolic blood pressure164 mm[Hg]8480-6S
1931-01-05Diastolic blood pressure94 mm[Hg]8462-4S
1931-01-05Heart rate78 /min8867-4S
1931-01-05Respiratory rate16 /min9279-1S
1931-01-05Body temperature36.6 Cel8310-5S
1931-01-05Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1931-01-20Body height157 cm8302-2S
1931-01-20Body weight70 kg29463-7S
1931-01-20Body mass index (BMI) [Ratio]28.4 kg/m239156-5S
1931-01-20Systolic blood pressure154 mm[Hg]8480-6S
1931-01-20Diastolic blood pressure90 mm[Hg]8462-4S
1931-01-20Heart rate76 /min8867-4S
1931-01-20Respiratory rate16 /min9279-1S
1931-01-20Body temperature36.7 Cel8310-5S
1931-01-20Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1931-02-03Body height157 cm8302-2S
1931-02-03Body weight69.6 kg29463-7S
1931-02-03Body mass index (BMI) [Ratio]28.2 kg/m239156-5S
1931-02-03Systolic blood pressure142 mm[Hg]8480-6S
1931-02-03Diastolic blood pressure84 mm[Hg]8462-4S
1931-02-03Heart rate74 /min8867-4S
1931-02-03Respiratory rate16 /min9279-1S
1931-02-03Body temperature36.6 Cel8310-5S
1931-02-03Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1931-02-17Body height157 cm8302-2S
1931-02-17Body weight69.2 kg29463-7S
1931-02-17Body mass index (BMI) [Ratio]28.1 kg/m239156-5S
1931-02-17Systolic blood pressure136 mm[Hg]8480-6S
1931-02-17Diastolic blood pressure82 mm[Hg]8462-4S
1931-02-17Heart rate72 /min8867-4S
1931-02-17Respiratory rate16 /min9279-1S
1931-02-17Body temperature36.6 Cel8310-5S
1931-02-17Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1931-03-03Body height157 cm8302-2S
1931-03-03Body weight68.9 kg29463-7S
1931-03-03Body mass index (BMI) [Ratio]28 kg/m239156-5S
1931-03-03Systolic blood pressure132 mm[Hg]8480-6S
1931-03-03Diastolic blood pressure80 mm[Hg]8462-4S
1931-03-03Heart rate72 /min8867-4S
1931-03-03Respiratory rate16 /min9279-1S
1931-03-03Body temperature36.6 Cel8310-5S
1931-03-03Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Blood pressure below 130/80 mmHg in the clinic and at home within two months of starting treatment, and lower if tolerated1931-03-03active132/80 in the clinic and 130/78 at home on losartan 50 mg and dapagliflozin; losartan increased to 100 mg
Urine albumin-to-creatinine ratio lower by at least 30% at the three-month check on treatment1931-03-03active240 and 228 mg/g at baseline; repeat due at three months on treatment
No NSAIDs or other avoidable kidney harms; every medicine checked against her kidney function1931-03-03completedNaproxen stopped at intake; acetaminophen used instead; medicines checked at every visit
An informed decision about APOL1 genetic testing, made by her after counseling1931-01-20completedCounseled at the consultation; she chose to defer the test and may ask for it at any time
She understands her stage, her risk and the kidney replacement options, and her wishes are recorded, long before any decision is needed1931-02-17completedKidney education session completed; wishes recorded at the annual wellness visit

Interventions

InterventionStatusGuideline
Nephrology consultation for reduced kidney function (race-free eGFR 38) with albuminuria of uncertain cause, a 5-year kidney failure risk above 5% if the disease proves chronic, and APOL1 genetic counselingcompletedGL-KDIGO-CKD-2024, GL-CMID-2026
Confirm and stage the kidney disease: race-free eGFR from creatinine with cystatin C, repeat urine albumin-to-creatinine ratio, urinalysis with microscopy, kidney ultrasound, a monoclonal protein screen (serum protein electrophoresis and free light chains), hepatitis B, hepatitis C and HIV tests, and any earlier results she can obtaincompletedGL-KDIGO-CKD-2024, GL-NKF-ASN-2021, GL-CKDEPI-2021
Blood pressure: a validated home monitor with readings twice a day for seven days to confirm the diagnosis; sodium below 2 g a day; recheck in two weekscompletedGL-AHA-HTN-2025, GL-KDIGO-BP-2021, GL-CMID-2026
Stop over-the-counter naproxen and use acetaminophen for knee aching; avoid all NSAIDs; tell every clinician and pharmacist about her kidneys before new medicines or contrast dyecompletedGL-KDIGO-CKD-2024, GL-CMID-2026
Anemia and mineral and bone checks: hemoglobin with iron studies, calcium, phosphate, intact PTH and 25-hydroxyvitamin D at baselinecompletedGL-KDIGO-CKD-2024, GL-KDIGO-MBD-2017, GL-CMID-2026
Baseline ECG, TSH for tiredness, a lipid panel once at diagnosis, A1c to screen for diabetes, and a PHQ-9completedGL-CMID-2026, GL-AHA-HTN-2025, GL-USPSTF-DEP-2023
On the nephrologist's advice: losartan 50 mg daily with potassium and creatinine in two weeks, then dapagliflozin 10 mg daily with a further check at two to four weeks, then losartan increased to the highest dose tolerated; sick-day rules for both; atorvastatin 20 mg; vitamin D3 1,000 units daily with PTH and vitamin D again at three months; blood pressure goal below 130/80 and a systolic below 120 if toleratedcompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-KDIGO-MBD-2017, GL-CMID-2026
APOL1 genetic testing offered after counseling on what a result would and would not change, on privacy, and on what it could mean for relatives; her decision to defer recorded, with the offer left opencompletedGL-KDIGO-CKD-2024
Kidney education session on the kidneys and the treatment options if they fail (transplant, home and center dialysis, and conservative kidney management), long before any decision is needed; kidney diet session with the dietitiancompletedGL-KDIGO-CKD-2024, GL-CMID-2026
Vaccines for chronic kidney disease: high-dose influenza, PCV20 and two doses of HepB-CpG (she was not immune), then RSV, recombinant zoster and COVID-19, spaced at her requestcompletedGL-CDC-IMZ-2026
Dapagliflozin 10 mg daily started now that potassium and creatinine are stable on losartancompletedGL-KDIGO-CKD-2024, GL-CMID-2026
Losartan increased to 100 mg; potassium and creatinine in two to four weeks; urine albumin-to-creatinine ratio, hemoglobin, PTH and vitamin D at three months on treatment; nephrology review at three monthscompletedGL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Ida B. Wells National Park Service government
SRC-0002 Ida B. Wells-Barnett (biography) National Women's History Museum biography
SRC-0003 Wells-Barnett, Ida (1862-1931), Women in World History: A Biographical Encyclopedia Encyclopedia.com (Gale) biography
SRC-0004 DeCosta-Willis M. Wells-Barnett, Ida B. Tennessee Encyclopedia (Tennessee Historical Society) biography
SRC-0005 Guide to the Ida B. Wells Papers 1884-1976 (biographical note) University of Chicago Library, Hanna Holborn Gray Special Collections Research Center other
SRC-0006 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the race-free eGFR values (creatinine 40, creatinine with cystatin C 38) and the race-based value for comparison, the G3b A2 staging, the kidney failure risk estimate, the sequencing of losartan and dapagliflozin with potassium and creatinine checks, the statin for an adult over 50 with eGFR below 60, vitamin D replacement, and the APOL1 counseling.
provenance reviewnot_startedSources: the National Park Service, the National Women's History Museum, Women in World History (Encyclopedia.com), the Tennessee Encyclopedia and the University of Chicago Library finding aid. The Library of Congress, the Chicago Defender, Paula Giddings's biography and Crusade for Justice could not be read directly.
safe messaging reviewnot_startedNo mental health claim is made; mood screening is synthetic and below the threshold for a safety assessment. Her death is stated once, without speculation about its cause beyond kidney disease or uremia as the sources give it.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.